About NeoClone

Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ways to discover and develop antibodies. As they refined the process to make better antibodies (what is now the NeoAb process), they established a reagent catalog as well as a service business to make high-quality antibodies for others.

By 2002 the founders realized a need to bring in business expertise to help grow the company by leveraging its ability to make excellent antibodies. This change in direction is the foundation of what NeoClone is today - a company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostics. As a result of these efforts, we now have over 1000 customers in 30+ countries.

NeoClone has always been a research-focused company with an emphasis on emerging antibody technologies.  Reactivation is our proprietary technology for selecting, enriching, and amplifying murine or human antigen-specific antibody-producing cells. We stimulate only the class-switched (IgG), affinity matured Ig-secretors to proliferate, which increases the number of antigen -specific Ig-secreting cells relative to non-specific Ig-secreting cells. If you want to know more about this exciting technology and how it might help make better antibodies, ask to talk to our Director of Research, Rachel Kravitz, PhD, at 608-260-8190.

To poise ourselves for future success, we've continued to refine our antibody development abilities. In 2014, we added antibody phage display technology to help us develop the diverse and specific antibody repertoire to certain difficult targets that might be difficult to achieve with hybridoma technology alone. We have now developed camelid (VHH) antibody capabilities so we can service the rapidly growing therapeutics market. We have been offering this service since late 2015.

Want to know more? This e-mail address is being protected from spambots. You need JavaScript enabled to view it , NeoClone's CEO, will be happy to help.